HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sertraline treatment of elderly patients with depression and cognitive impairment.

AbstractBACKGROUND:
There is little information on the efficacy and side effects of antidepressant treatment in elderly patients with combined depression and cognitive impairment without dementia (DEP-MCI), and it is unclear if cognitive performance improves with antidepressant response in these patients.
METHODS:
In 39 elderly DEP-MCI patients, changes in depression and cognitive impairment were evaluated with open sertraline treatment up to 200 mg/day for 12 weeks.
RESULTS:
Of the 26 completers, 17 were responders and nine were non-responders. Diagnostic subtype of depression was unrelated to response. ANCOVA on WAIS-R digit symbol percent change scores revealed a significant effect for responder status (F = 5.59, p < 0.03), and age (F = 0.24, p < 0.64) and education (F = 1.64, p < 0.22) were not significant covariates. From pre-trial to post-trial, responders improved in WAIS-R digit symbol percent change scores (Mean -10% SD 24) while non-responders declined (Mean 14% SD 18; t = 2.60, p < 0.02). Other neuropsychological measures were unrelated to response. Percent change in HRSD scores showed significant inverse correlations with percent change in several cognitive measures.
CONCLUSIONS:
DEP-MCI patients showed moderate clinical response to sertraline treatment. When responders were compared to non-responders, cognitive improvement was limited to one measure of attention and executive function. Overall, there was little cognitive improvement with antidepressant treatment. The findings indirectly suggest that lack of improvement in cognition following treatment of depression in DEP-MCI patients may be associated with increased risk of meeting diagnostic criteria for dementia during follow-up.
AuthorsD P Devanand, Gregory H Pelton, Kristin Marston, Yesenia Camacho, Steven P Roose, Yaakov Stern, Harold A Sackeim
JournalInternational journal of geriatric psychiatry (Int J Geriatr Psychiatry) Vol. 18 Issue 2 Pg. 123-30 (Feb 2003) ISSN: 0885-6230 [Print] England
PMID12571820 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
CopyrightCopyright 2003 John Wiley & Sons, Ltd.
Chemical References
  • Antidepressive Agents
  • Sertraline
Topics
  • Aged
  • Aged, 80 and over
  • Antidepressive Agents (blood, therapeutic use)
  • Cognition Disorders (complications, drug therapy)
  • Depressive Disorder (complications, drug therapy)
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Geriatric Assessment (methods)
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Psychiatric Status Rating Scales
  • Sertraline (blood, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: